La Unitat de Trasplantament Renal del Servei de Nefrologia de l\u2019Hospital Universitari de Bellvitge ha desenvolupat i mostrat l\u2019efic\u00e0cia d\u2019un nou test immunol\u00f2gic per prevenir una de les infeccions oportunistes m\u00e9s freq\u00fcents i greus posteriors a un trasplantament, com \u00e9s el citomegalovirus. Aquesta informaci\u00f3 deriva dels bons resultats obtinguts aplicant aquest test en un estudi\u00a0que publica avui la prestigiosa revista cient\u00edfica Clinical Infectious Diseases.<\/p>\n
L\u2019estudi d\u2019efic\u00e0cia cl\u00ednica ha estat coordinat per investigadors de l\u2019Hospital Universitari de Bellvitge i l\u2019Institut d’Investigaci\u00f3\u00a0Biom\u00e8dica de Bellvitge (IDIBELL) i hi han participat tamb\u00e9 l\u2019Hospital Universitari Vall d\u2019Hebron, la Fundaci\u00f3 Puigvert, l\u2019Hospital Cl\u00ednic de Barcelona i l\u2019Hospital Universitario Miguel Servet de Saragossa. El treball ha incl\u00f2s el seguiment de 160 pacients durant un per\u00edode de dotze mesos.<\/p>\n
La infecci\u00f3 oportunista per citomegalovirus \u00e9s la m\u00e9s freq\u00fcent i tamb\u00e9 la m\u00e9s greu \u2013fins al punt que pot arribar a ser mortal\u2013 entre els pacients que han rebut un trasplantament renal. Per aquest motiu, fins ara totes les persones trasplantades eren tractades preventivament contra aquest virus de manera generalitzada. Aquesta ter\u00e0pia, tanmateix, no \u00e9s inn\u00f2cua, ja que t\u00e9 efectes t\u00f2xics i tamb\u00e9 pot interferir en el maneig del tractament immunosupressor i posar en risc de rebuig l\u2019\u00f2rgan trasplantat.<\/p>\n
La realitzaci\u00f3 d\u2019aquest test, dissenyada per investigadors del mateix Hospital Universitari de Bellvitge i l\u2019IDIBELL, evitaria prescriure aquesta ter\u00e0pia antiviral quan no \u00e9s necess\u00e0ria. El test s\u2019aplica als pacients que acaben de rebre un trasplantament renal i examina com responen enfront al citomegalovirus els limf\u00f2cits T (c\u00e8l\u00b7lules sangu\u00ednies involucrades en la resposta immunit\u00e0ria). Si queda establert que el pacient presenta una bona resposta immunit\u00e0ria al citomegalovirus, se li pot estalviar el tractament antiviral preventiu contra aquest agent infecci\u00f3s.<\/p>\n
El Dr. Oriol Bestard, cap de la Unitat de Trasplantament Renal de l\u2019Hospital Universitari de Bellvitge i un dels autors principals de l\u2019estudi, posa de manifest que \u00e9s la primera vegada a nivell mundial que es demostra l\u2019efic\u00e0cia cl\u00ednica d\u2019un test per prevenir la infecci\u00f3 pel citomegalovirus dins d\u2019un assaig cl\u00ednic d\u2019intervenci\u00f3, prospectiu i aleatoritzat. Segons destaca, \u201c\u00e9s un pas endavant cap a la medicina personalitzada, en qu\u00e8 les decisions terap\u00e8utiques estan dirigides d\u2019acord amb el risc individual de cada pacient\u201d. Tamb\u00e9 afirma que aquest aven\u00e7 \u201cpot canviar significativament la medicina del trasplantament, ja que evitar\u00e0 tractaments t\u00f2xics innecessaris i alhora suposar\u00e0 un estalvi econ\u00f2mic important\u201d.<\/p>\n
L\u2019estudi s\u2019ha fet amb pacients que han rebut un trasplantament de rony\u00f3, per\u00f2 els investigadors destaquen que es tracta d\u2019una prova igualment \u00fatil per ajudar a la prevenci\u00f3 de la mateixa infecci\u00f3 en la resta de trasplantaments d\u2019\u00f2rgans s\u00f2lids, aix\u00ed com en els pacients que reben un trasplantament de medul\u00b7la \u00f2ssia, tot i que calen estudis addicionals en aquests darrers escenaris per demostrar la seva efic\u00e0cia, alguns d\u2019ells ja en marxa i tamb\u00e9 liderats des de l\u2019Hospital de Bellvitge.<\/p>\n
A partir d\u2019aquestes dades, s\u2019espera poder comen\u00e7ar a utilitzar aquesta nova tecnologia de forma protocol\u00b7litzada en la pr\u00e0ctica cl\u00ednica habitual en un breu per\u00edode de temps.<\/p>\n","protected":false},"excerpt":{"rendered":"
Un assaig fet a cinc hospitals ha demostrat l\u2019efic\u00e0cia cl\u00ednica d\u2019aquesta nova eina diagn\u00f2stica. El nou test suposa un pas endavant cap a la medicina personalitzada en el camp dels trasplantaments.<\/p>\n","protected":false},"author":6,"featured_media":10372,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[334,339],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-08 21:36:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7330"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7330"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7330\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10372"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}